Picture Kentro Design Is Key to Your Success Berlin 650x100px
Document › Details

Robocath SAS. (11/2/20). "Press Release: Robocath Finalizes Creation of the Joint Venture with MicroPort through Its Medical Robotic Subsidiary MedBot". Rouen.

Region Region China
Organisations Organisation Robocath SAS
  Organisation 2 MicroPort Scientific Corporation (HKG:853)
  Group MicroPort Scientific (Group)
Products Product AB Sciex TripleTOF® 6600 System
  Product 2 mass spectrometry-based analysis of biopharmaceutical
Index term Index term MicroPort Scientific–Robocath: cardiovascular devices, 202004– collab strategic agreem to set up joint venture in China for vascular robotics platform
Persons Person Goffart, Lucien (Robocath 202004 CEO)
  Person 2 He, Alex (MicroPort 202004 General Manager of MedBot)

Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces creation of the joint venture with MicroPort Scientific Corporation ‘MicroPort’, through ‘MedBot’, its MicroPort MedBot (Shanghai) Co. Ltd subsidiary. This strategic partnership will enable the commercialization in China of its first robotic-assisted platform, R-One™. Both companies will also carry out research and development activities as agreed per the terms of the investment announced in April 2020. Robocath will hold 49% of this joint venture, 51% will be owned by MedBot.

Through this deal, Robocath will begin the commercialization of its first robotic-assisted platform in China, today the world’s biggest market in interventional cardiology. This expansion will be facilitated by local manufacturing of consumables and robotic assembly to ensure optimal distribution of Robocath products in this market. The testing, clinical and regulatory activities required to receive National Medical Products Administration (NMPA) approval for R-One will begin immediately. Both companies will also carry out research and development activities related to the next long-distance generation of remote control over 5G network technologies and will develop artificial intelligence algorithms to be used with robotic-assisted platforms.

“We are excited to take this new step in our development which will permit us to rapidly penetrate the sector’s leading market,” said Philippe Bencteux, chairman and founder of Robocath. “We are impressed with the resources made available by our partner to fast-track the approval of our product in China.”

“Since the announcement of our strategic partnership last April, we have strengthened our discussions with all of the Robocath team in order to establish this common structure which will undoubtedly ensure the commercial success of the R-One robotic-assisted platform in the Chinese market,” said Dr. Alex He, general manager of MedBot.

“We are looking forward to starting this collaboration. Together, we share the conviction that the future of interventional medicine is based on robotics and artificial intelligence. Over the next few years, this strategic partnership will enable us to accelerate our commercial deployment and strengthen our technological know-how to make Robocath a major global player in the field of vascular robotics,” added Lucien Goffart, CEO of Robocath.


Founded in 2014, MedBot develops intelligent surgical robotic systems and solutions. MedBot is committed to meeting the most cutting-edge development needs of minimally invasive surgery, and innovatively providing integrated intelligent surgical solutions that can save patients’ lives or improve their quality of life. Following years of research and development, innovation and industrial accumulation, MedBot has grown to become a medical robot company that masters the underlying technology in the entire chain. MedBot’s three flagship products in the three major segments, namely the Toumai™ laparoscopic surgical robot, Skywalker™ joint replacement surgical robot and DFVision™ three-dimensional electronic laparoscope, have entered the special approval procedure (Green Path) for innovative medical devices at the National Medical Products Administration (NMPA), becoming the only surgical robot company with three ‘Green Path’ grants in the People’s Republic of China (PRC). Its current business covers five areas, including endoscopy, orthopaedics, vascular intervention, natural orifice, and percutaneous puncture.


MicroPort® was founded in 1998 in ZJ Hi-Tech Park in Shanghai China, where a group of dedicated individuals joined together by the common belief that advancements in medical technology could transform patients’ lives in China and around the globe. Over the last two decades, MicroPort® has taken important steps towards fulfilling its mission of providing access to the best means of prolonging and reshaping lives.

Today, MicroPort® is focused in covering 10 major areas including Cardiovascular Intervention & Structural Heart Diseases, Electrophysiology & Cardiac Rhythm Management, Orthopedics & Soft Tissue Repair, Endovascular & Peripheral Vascular Diseases, Neurovascular Intervention & Neurosciences, Life Sciences (Endocrine Management), Surgical Devices & Medical Robotics, Urology & Gynecology & Respiratory & Gastroenterology, Aesthetics & Rehabilitation, and In vitro Diagnostics & Medical Imaging.

Thanks to over 300 MicroPort® devices currently approved for use in nearly 10,000 hospitals worldwide, one of our devices is used every six seconds. With a vast global footprint of R&D and manufacturing sites (Shanghai; Memphis, TN in the United States; Clamart in France; Saluggia in Italy; Santo Domingo in the Dominican Republic), a strong focus on technology innovation with over 4,700 patent applications, and a global workforce of over 7,000 employees, MicroPort® is committed to its vision of building a People Centric Consortium of companies focused on Emerging Medical Technologies.


Morgane Le Mellay
FR/UK: +33 (0)6 34 40 91 25

Juliette Schmitt-dos Santos / Jo Reeder /
UK: + 44 1273 675 100 / US: + 1 617 202 4491

Record changed: 2024-03-30


Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Robocath SAS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News Healthtech Company Mika 650x300px

» top